Dr. Farolino studies a rare condition known as paraneoplastic intestinal pseudo-obstruction (CIPO), which can occur in patients with certain cancers, like small cell lung cancer. CIPO causes severe digestive problems, making it difficult for patients to eat and absorb nutrients. Through her research, she explores innovative treatment options to help alleviate these symptoms, focusing on how certain medications might improve the situation where traditional treatments have failed. Her goal is to provide less invasive solutions to enhance patients' well-being and minimize the need for more complicated surgeries.
Key findings
In her 2012 study, treatment with rituximab and cyclophosphamide improved the condition of a patient suffering from CIPO after previous methods were ineffective.
This new treatment approach offers an alternative to invasive surgeries, potentially improving the quality of life for cancer patients experiencing intestinal complications.
The research highlights the importance of personalized medicine, where specific combinations of treatments are tailored to the individual needs of patients.
Frequently asked questions
Does Dr. Farolino study paraneoplastic intestinal pseudo-obstruction?
Yes, Dr. Farolino focuses specifically on paraneoplastic intestinal pseudo-obstruction, especially in patients with cancer.
What treatments has Dr. Farolino researched for intestinal issues?
She has researched the use of rituximab and cyclophosphamide as a treatment for intestinal problems related to cancer.
Is Dr. Farolino's work relevant to cancer patients with digestive problems?
Yes, her research is directly aimed at helping cancer patients who suffer from intestinal complications.
What is the significance of Dr. Farolino's findings?
Her findings provide new treatment options that can improve quality of life for patients without resorting to invasive procedures.
Publications in plain English
A novel approach to paraneoplastic intestinal pseudo-obstruction.
2012
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
Badari A, Farolino D, Nasser E, Mehboob S, Crossland D
Plain English This study looked at a rare condition called paraneoplastic intestinal pseudo-obstruction (CIPO) in a patient with small cell lung cancer. Researchers found that treating the patient with a combination of two drugs, rituximab and cyclophosphamide, improved their condition after previous treatments had failed. This matters because it offers a new, less invasive option for patients suffering from CIPO, potentially improving their quality of life without needing complicated surgeries.
Who this helps: This helps cancer patients experiencing intestinal issues related to their disease.